Abstract: SA-OR36
Hospital Health Care Costs Following Incident CKD in Japan, Sweden, and the United States
Session Information
- Epidemiology of CKD Progression: Who, Why, and When?
November 04, 2023 | Location: Room 119, Pennsylvania Convention Center
Abstract Time: 05:42 PM - 05:51 PM
Category: CKD (Non-Dialysis)
- 2301 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention
Authors
- Tangri, Navdeep, University of Manitoba Max Rady College of Medicine, Winnipeg, Manitoba, Canada
- Svensson, Maria K., Uppsala Universitet, Uppsala, Sweden
- Sofue, Tadashi, Kagawa Daigaku, Takamatsu, Kagawa, Japan
- Bodegard, Johan, AstraZeneca, Gothenburg, Sweden
- Adamsson Eryd, Samuel, AstraZeneca, Gothenburg, Sweden
- Thuresson, Marcus, Statisticon AB, Uppsala, Sweden
- Gustafsson, Stefan, Sence Research AB, Uppsala, Sweden
Background
Chronic kidney disease (CKD) affects an estimated 10% of the global population. It is associated with cardiorenal complications (e.g. end stage kidney disease and heart failure [HF]), premature mortality, and high healthcare burden and costs. Here we assess hospital healthcare costs following incident CKD.
Methods
This study uses secondary data from electronic health records or claims data sources from Japan, Sweden and the US. Adult patients with incident CKD (defined as having either: two estimated glomerular filtration rate [eGFR] measurements ≥ 90 days apart of ≤ 60 mL/min/1.73 m2 or an eGFR measurement ≤ 60 mL/min/1.73 m2 followed by a CKD diagnosis) were identified during 2016–2023. Cumulative costs per patient for hospitalizations associated with a main diagnosis of HF, CKD, myocardial infarction (MI), stroke or peripheral artery disease (PAD) were summarized for up to 5 years after index (date of second eGFR measurement or CKD diagnosis).
Results
Overall, 549 884 patients were included (Japan, 74 285; Sweden, 76 133; US, 399 466). In Japan, Sweden and the US, respectively: median ages were 81, 78 and 74 years; 54%, 48% and 37% were males; and across countries the majority (68%) of patients did not have type 2 diabetes. Median eGFR measurements were similar across countries. Hospital healthcare costs associated with cardiorenal events (CKD and HF) were high (Figure). Atherosclerotic cardiovascular disease (MI, stroke and PAD) contributed less to hospital healthcare costs.
Conclusion
Hospital healthcare costs were high and largely driven by cardiorenal events (CKD and HF) among patients with incident CKD. This was consistent across all three countries, despite differences in healthcare systems.
Funding
- Commercial Support – AstraZeneca